These results indicated that RAS signaling pathway may be triggered by ETS1 in a KRAS mutation-independent manner by hypoxia (Figure 5E), suggesting that CRC patients with WT KRAS status should consider hypoxia-target therapy or combination with EGFR inhibitor if failure of mono-EGFR inhibitor treatment. This evidence concerns the gene KRAS and colorectal carcinoma.